On October 10, "Jianshi Technology," a portfolio company invested in by ChenDe Capital—the sub-fund backed by the master fund managed by Yuanhe Chencun—officially listed on the Hong Kong Stock Exchange, with stock code: 9877.HK.

Founded in 2011, JianShi Technology is a China-based medical device company dedicated to developing innovative products for the treatment of structural heart diseases. Focusing on the large, underpenetrated, and rapidly growing market for structural heart disease therapies, JianShi Technology has created a comprehensive suite of treatment solutions tailored to various types of structural heart conditions—such as tricuspid valve disease, aortic valve disease, mitral valve disease, and heart failure.

To meet the medical needs of patients with structural heart disease, Juntai Technology has developed a comprehensive product portfolio covering all types of structural heart conditions. At the core of Juntai Technology’s offerings is LuX-Valve, its first-generation, independently developed transcatheter tricuspid valve replacement system specifically designed for patients with severe tricuspid regurgitation and high surgical risk. Another key product, Ken-Valve, is tailored to treat severe aortic regurgitation and addresses a patient population whose needs far exceed those currently met by transcatheter aortic valve replacement systems, which are indicated only for aortic stenosis. In addition, Juntai Technology is actively advancing eight additional cutting-edge products in development, targeting various valve diseases and heart failure conditions.

Jianshi Technology boasts comprehensive manufacturing capabilities, with dedicated production lines for stents, valves, and delivery systems. Currently, its annual production capacity ranges from 4,000 to 5,000 sets, and the company anticipates further expanding its annual output in the future.

Moving forward, JianShi Technology is committed to becoming a globally leading medical device platform. The company will continue to accelerate the development and commercialization of its pipeline products, while deepening its comprehensive, diversified, and robust portfolio focused on heart valve diseases and heart failure treatments.